Skip to main content
Sun Pharma Advanced Research Company Ltd. logo

Sun Pharma Advanced Research Company Ltd. — Investor Relations & Filings

Ticker · SPARC ISIN · INE232I01014 LEI · 3358001Y3QHHUNROTJ51 BSE.NS Professional, scientific and technical activities
Open in API
Filings indexed 638 across all filing types
Latest filing 2025-11-12 Regulatory Filings
Country IN India
Listing BSE.NS SPARC

About Sun Pharma Advanced Research Company Ltd.

https://www.sparc.life

Sun Pharma Advanced Research Company Ltd. (SPARC) is a clinical-stage biopharmaceutical company dedicated to the research and development of innovative pharmaceutical products and drug delivery systems. SPARC focuses on creating new chemical entities (NCEs), new biological entities (NBEs), and reformulated products that address significant unmet medical needs. The company utilizes proprietary technology platforms, such as WrapMatrix and Nanotecton, to enhance the efficacy and safety of treatments. Its research pipeline primarily targets therapeutic areas including oncology, neurodegeneration, and ophthalmology. SPARC advances candidates through various stages of clinical trials to provide value-added medicines and novel therapeutic solutions for complex health conditions, leveraging its expertise in formulation and clinical development to improve patient outcomes globally.

Recent filings

Filing Released Lang Actions
Copy of Newspaper Publication
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges (NSE and BSE) regarding a disclosure under Regulation 47 of SEBI Listing Obligations and Disclosure Requirements. It mentions the publication of an advertisement containing an extract of the financial results (Standalone and Consolidated) for the second quarter and half year ended September 30, 2025. The letter states that the advertisement was published in newspapers and is also available on the company's website. The document is essentially a notification about the publication of financial results extracts in newspapers and on the website, not the full financial report itself. The document length is 7,182 characters, which is relatively short and consistent with an announcement rather than a full report. There is no detailed financial data or analysis included, only a reference to the extract of financial results. Therefore, this document fits the category of a Regulatory Filing (RNS) as it is a regulatory announcement of the publication of financial results extracts, not the full report or detailed financial statements.
2025-11-12 English
Outcome of Board Meeting
Interim / Quarterly Report Classification · 95% confidence The document is a detailed announcement from Sun Pharma Advanced Research Company Limited dated November 10, 2025, reporting the outcome of a Board Meeting where the unaudited standalone and consolidated financial results for the second quarter and half year ended September 30, 2025, were considered and approved. It includes extensive financial data such as income statements, balance sheets, and cash flow statements for the period, along with notes explaining the accounting standards and other relevant details. The document is about quarterly and half-year financial results, which are unaudited and include substantive financial data and analysis. This matches the definition of an Interim / Quarterly Report (IR). It is not a brief announcement or a certification letter, but a full financial report for a period shorter than a fiscal year. Therefore, the correct classification is IR with high confidence. H1 2026
2025-11-10 English
Board Meeting — Board Meeting Intimation
Regulatory Filings
2025-10-31 English
Board Meeting — Financial Results
Board/Management Information Classification · 95% confidence The document is a letter addressed to stock exchanges informing about a scheduled Board Meeting to consider and approve unaudited financial results for the quarter and half year ended September 30, 2025. It also mentions the closure of the trading window for insiders. The document is an announcement of an upcoming board meeting and related compliance matters, not the financial results themselves or a detailed report. The length is short (1870 characters), and it serves as an intimation under SEBI regulations about the board meeting and trading window closure. Therefore, it fits best under Board/Management Information (MANG) as it relates to board meeting scheduling and compliance disclosures.
2025-10-31 English
Spurt in Volume
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the National Stock Exchange of India regarding compliance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It confirms that all required disclosures have been made and that there is no undisclosed information. The document is short (1330 characters) and serves as a clarification or compliance confirmation rather than a financial report or detailed filing. It does not contain financial data, management changes, voting results, or other specific report content. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements and compliance confirmations.
2025-10-29 English
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Regulatory Filings Classification · 95% confidence The document is a Confirmation Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended September 30, 2025. It is addressed to stock exchanges and depositories and confirms the dematerialisation of securities and related compliance. The document is a regulatory compliance certificate rather than a financial report or announcement of financial results. It does not contain financial statements or detailed financial data. The document length is 3408 characters, which is relatively short and consistent with a regulatory filing or certification. Therefore, it fits best under Regulatory Filings (RNS) as it is a compliance certificate related to securities regulations and not a financial report or announcement.
2025-10-09 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.